PubMed:32712670 / 0-513 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":29,"end":38},"obj":"CHEBI:31781"},{"id":"T2","span":{"begin":29,"end":38},"obj":"DG_23"},{"id":"T3","span":{"begin":29,"end":38},"obj":"CHEBI:31781"},{"id":"T4","span":{"begin":48,"end":57},"obj":"DG_13"},{"id":"T5","span":{"begin":67,"end":82},"obj":"UBERON:0002450"},{"id":"T6","span":{"begin":122,"end":127},"obj":"GO:0007567"},{"id":"T7","span":{"begin":153,"end":164},"obj":"GO:0007565"},{"id":"T8","span":{"begin":233,"end":247},"obj":"CHEBI:35705"},{"id":"T9","span":{"begin":233,"end":247},"obj":"CHEBI:35705"},{"id":"T10","span":{"begin":318,"end":327},"obj":"GO:0007565"},{"id":"T11","span":{"begin":334,"end":349},"obj":"UBERON:0002450"},{"id":"T12","span":{"begin":354,"end":360},"obj":"UBERON:0000395"},{"id":"T13","span":{"begin":361,"end":367},"obj":"UBERON:0001637"},{"id":"T14","span":{"begin":405,"end":414},"obj":"CHEBI:31781"},{"id":"T15","span":{"begin":405,"end":414},"obj":"DG_23"},{"id":"T16","span":{"begin":405,"end":414},"obj":"CHEBI:31781"},{"id":"T17","span":{"begin":419,"end":428},"obj":"DG_13"},{"id":"T18","span":{"begin":480,"end":491},"obj":"GO:0007565"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies.\nSTUDY QUESTION: Does HIV protease inhibitor (PI)-based combination antiretroviral therapy (cART) initiated at periconception affect key events in early pregnancy, i.e. decidualization and spiral artery remodeling?\nSUMMARY ANSWER: Two PIs, lopinavir and darunavir, currently offered as cART options in HIV-positive pregnancies were evaluated, and w"}

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":165},"obj":"Sentence"},{"id":"T2","span":{"begin":166,"end":181},"obj":"Sentence"},{"id":"T3","span":{"begin":182,"end":379},"obj":"Sentence"},{"id":"T4","span":{"begin":380,"end":395},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":165},"obj":"Sentence"},{"id":"T2","span":{"begin":166,"end":181},"obj":"Sentence"},{"id":"T3","span":{"begin":182,"end":379},"obj":"Sentence"},{"id":"T4","span":{"begin":380,"end":395},"obj":"Sentence"}],"text":"Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies.\nSTUDY QUESTION: Does HIV protease inhibitor (PI)-based combination antiretroviral therapy (cART) initiated at periconception affect key events in early pregnancy, i.e. decidualization and spiral artery remodeling?\nSUMMARY ANSWER: Two PIs, lopinavir and darunavir, currently offered as cART options in HIV-positive pregnancies were evaluated, and w"}